Cel Sci Corporation (CVM)

[H2R]

101.7 month vs.. 55.2 months mOS

Rather impressive.

? 101.7 months median overall survival in the lower risk Multikine treatment cohort vs. 55.2 months for standard of care;

? 16.0% early response rate for Multikine vs. 0% for standard of care;

? 17.6% death rate for early responders in the lower-risk treatment cohort vs. 42.7% for non-responders;

? Progression free survival presents a 0.76 hazard ratio;

? Overall survival presents a 0.68 hazard ratio.
? 16.0% early response rate for Multikine vs. 0% for standard of care;

? 17.6% death rate for early responders in the lower-risk treatment cohort vs. 42.7% for non-responders;

? Progression free survival presents a 0.76 hazard ratio;

? Overall survival presents a 0.68 hazard ratio.

Best of luck with your investments!